BIOPHARMA
ByCan Novo Nordisk’s Lawsuit Against Eli Lilly Push the $100 Billion GLP-1 Market Toward More Transparent, Evidence-Based Advertising?
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to formally challenge Eli…
Roche’s Gazyva Wins Second FDA Priority Review in Months — Is Obinutuzumab Becoming Nephrology’s Next Blockbuster?
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement that the FDA…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
